1.1100
25-十一月-24 12:40:01
15 分钟延时
股票
+0.0300
+2.78%
今日范围
1.0600 - 1.1200
ISIN
N/A
来源
NASDAQ
Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
12 1月 2021 07:05:00 条件 Nasdaq GlobeNewswire
Clearside Biomedical Announces Pricing of $12 Million Registered Direct Offering
06 1月 2021 07:05:00 条件 Nasdaq GlobeNewswire